102074-60-2

Usage

Uses

Used in Pharmaceutical Research:
4-Pyridinemethanol,3-methoxy-(6CI,9CI) is used as a building block in pharmaceutical research for its potential medicinal properties. Its unique structure allows it to be a valuable component in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 4-Pyridinemethanol,3-methoxy-(6CI,9CI) is used as a key intermediate compound. Its presence in various chemical reactions enables the creation of a wide range of organic compounds with diverse applications.
Used in Antioxidant and Anti-Inflammatory Applications:
4-Pyridinemethanol,3-methoxy-(6CI,9CI) is used as an antioxidant and anti-inflammatory agent due to its potential medicinal properties. Its ability to combat oxidative stress and reduce inflammation makes it a promising candidate for the development of treatments for various diseases and conditions.
Used in Liver Disease Treatment Research:
4-Pyridinemethanol,3-methoxy-(6CI,9CI) is used in research for the treatment of liver diseases. Its potential role in addressing liver-related health issues is currently being explored, with the aim of developing effective therapies for liver conditions.

Upstream product

• 59786-32-2 methyl 3-methoxy-4-pyridinecarboxylate 
• 654663-32-8 3-methoxypyridine-4-carboxylic acid 
• 10128-72-0 methyl 3-hydroxypyridine-4-carboxylate 
• 10128-71-9 3-hydroxyisonicotinic acid 

Downstream Products

• 1849-52-1 3-methoxy-4-pyridinecarboxaldehyde 

Relevant academic research and scientific papers

INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR

Chromanone compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the inhibition of antigen presentation by HLA-DR.

AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is an aminopyrazine compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS

The present invention relates to novel Pyrazolo[4,3-d]Pyrimidine Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. The present invention also relate

Spin-Center Shift-Enabled Direct Enantioselective α-Benzylation of Aldehydes with Alcohols

Nature routinely engages alcohols as leaving groups, as DNA biosynthesis relies on the removal of water from ribonucleoside diphosphates by a radical-mediated "spin-center shift" (SCS) mechanism. Alcohols, however, remain underused as alkylating agents in synthetic chemistry due to their low reactivity in two-electron pathways. We report herein an enantioselective α-benzylation of aldehydes using alcohols as alkylating agents based on the mechanistic principle of spin-center shift. This strategy harnesses the dual activation modes of photoredox and organocatalysis, engaging the alcohol by SCS and capturing the resulting benzylic radical with a catalytically generated enamine. Mechanistic studies provide evidence for SCS as a key elementary step, identify the origins of competing reactions, and enable improvements in chemoselectivity by rational photocatalyst design.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS

The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatr